Free tool
Healthcare stocks
We cover 247 companies in the Healthcare sector. The median market value in the group is $3.80B. Across the group, the median move over the past trading day is +0.81%. 77% of the 238 with a 200-day average trade above it. Price change over the past year runs from −21.9% to +230.4% across the middle 80 percent of the group, with a median of +28.6%. Across the group, 2 companies currently carry a tier A volume signal.
Other lists in this group
Table
247 of 2,199 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| R1DY34.SA | Dr. Reddy's Laboratories Limited | $9.95B | Mid cap | −21.76% |
| PODD | Insulet Corporation | $9.92B | Mid cap | −56.52% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +67.40% |
| BIO-B | Bio-Rad Laboratories, Inc. | $9.77B | Mid cap | +47.78% |
| AVTR | Avantor, Inc. | $9.75B | Mid cap | +9.16% |
| OSCR | Oscar Health, Inc. | $9.55B | Mid cap | +85.10% |
| TWST | Twist Bioscience Corporation | $9.50B | Mid cap | +452.83% |
| WDH1.DE | Demant A/S | $9.39B | Mid cap | −5.53% |
| DEMANT.CO | Demant A/S | $9.37B | Mid cap | +17.33% |
| SYRE | Spyre Therapeutics, Inc. | $9.32B | Mid cap | +547.53% |
| KRK.WA | Krka, d. d. | $9.12B | Mid cap | +31.52% |
| PCVX | Vaxcyte, Inc. | $9.09B | Mid cap | +100.62% |
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −10.74% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +182.02% |
| IMVT | Immunovant, Inc. | $8.95B | Mid cap | +192.14% |
| QIA.DE | Qiagen N.V. | $8.85B | Mid cap | −11.42% |
| HQY | HealthEquity, Inc. | $8.83B | Mid cap | +20.55% |
| 4523.T | Eisai Co., Ltd. | $8.67B | Mid cap | +9.74% |
| BRKR | Bruker Corporation | $8.66B | Mid cap | +64.93% |
| ATR | AptarGroup, Inc. | $8.57B | Mid cap | −2.35% |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.51B | Mid cap | +3.09% |
| TGTX | TG Therapeutics, Inc. Common Stock | $8.48B | Mid cap | +96.32% |
| TXG | 10x Genomics, Inc. | $8.43B | Mid cap | +359.99% |
| ALKS | Alkermes plc | $8.26B | Mid cap | +69.69% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +14.26% |
| 6869.T | Sysmex Corporation | $7.42B | Mid cap | +5.65% |
| HIMS | Hims & Hers Health, Inc. | $7.41B | Mid cap | −26.15% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +62.22% |
| 2413.T | M3, Inc. | $7.39B | Mid cap | −20.12% |
| CAI | Caris Life Sciences, Inc. | $7.38B | Mid cap | −27.21% |
| RHC.AX | Ramsay Health Care Limited | $7.33B | Mid cap | +18.74% |
| HNGE | Hinge Health, Inc. | $7.25B | Mid cap | +63.19% |
| ALK-B.CO | ALK-Abelló A/S | $7.23B | Mid cap | +8.24% |
| SHL.AX | Sonic Healthcare Limited | $7.20B | Mid cap | −11.60% |
| CHE | Chemed Corporation | $7.11B | Mid cap | +19.61% |
| SRRK | Scholar Rock Holding Corporation | $7.09B | Mid cap | +74.77% |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +21.56% |
| PACS | PACS Group, Inc. | $7.00B | Mid cap | +272.69% |
| CGON | CG Oncology, Inc. | $7.00B | Mid cap | +210.58% |
| 3391.T | Tsuruha Holdings Inc. | $6.89B | Mid cap | +8.33% |
| 0126Z0.KS | SAMSUNG EPIS HOLDINGS | $6.82B | Mid cap | +13.26% |
| ORKA | Oruka Therapeutics, Inc. | $6.74B | Mid cap | +601.72% |
| 7747.T | Asahi Intecc Co., Ltd. | $6.68B | Mid cap | +58.61% |
| RADL3.SA | Raia Drogasil S.A. | $6.65B | Mid cap | +12.04% |
| E2XE34.SA | Exelixis, Inc. | $6.61B | Mid cap | +23.92% |
| HLUN-B.CO | H. Lundbeck A/S | $6.61B | Mid cap | +5.61% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +79.61% |
| HLUN-A.CO | H. Lundbeck A/S | $6.55B | Mid cap | +26.06% |
| BLTE | Belite Bio, Inc | $6.51B | Mid cap | +154.13% |
| 3088.T | MatsukiyoCocokara & Co. | $6.45B | Mid cap | −14.17% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +212.13% |
| COH.AX | Cochlear Limited | $6.38B | Mid cap | −53.16% |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +168.53% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +138.24% |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.24B | Mid cap | +93.10% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.17B | Mid cap | +142.74% |
| BLCO | Bausch + Lomb Corporation | $6.16B | Mid cap | +18.72% |
| ERAS | Erasca, Inc. | $6.16B | Mid cap | +1016.98% |
| BLCO.TO | Bausch + Lomb Corporation | $6.15B | Mid cap | +18.08% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.13B | Mid cap | +49.03% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +378.90% |
| STVN | Stevanato Group S.p.A. | $6.08B | Mid cap | +3.23% |
| TVTX | Travere Therapeutics, Inc. | $6.06B | Mid cap | +288.91% |
| CTEC.L | Convatec Group PLC | $6.06B | Mid cap | −2.30% |
| RDNT | RadNet, Inc. | $6.05B | Mid cap | +10.45% |
| DFTX | Definium Therapeutics, Inc. | $6.02B | Mid cap | +354.92% |
| T1FX34.SA | Teleflex Incorporated | $6.00B | Mid cap | +0.29% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +36.58% |
| TFX | Teleflex Incorporated | $5.94B | Mid cap | +10.85% |
| CRSP | CRISPR Therapeutics AG | $5.89B | Mid cap | +12.51% |
| XENE | Xenon Pharmaceuticals Inc. | $5.85B | Mid cap | +58.42% |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −19.07% |
| LGND | Ligand Pharmaceuticals Incorporated | $5.62B | Mid cap | +77.42% |
| MMED | MiniMed Group, Inc. | $5.60B | Mid cap | +2.33% |
| SHC | Sotera Health Company | $5.57B | Mid cap | +19.04% |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | +3.32% |
| GRFS | Grifols, S.A. | $5.44B | Mid cap | −17.62% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.23B | Mid cap | +20.73% |
| HAE | Haemonetics Corporation | $4.93B | Mid cap | +96.13% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +102.62% |
| 326030.KS | SK Biopharmaceuticals Co., Ltd. | $4.89B | Mid cap | −14.48% |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +209.16% |
| BLLN | BillionToOne, Inc. | $4.72B | Mid cap | −8.14% |
| LFST | LifeStance Health Group, Inc. | $4.69B | Mid cap | +127.83% |
| 000100.KS | Yuhan Corporation | $4.67B | Mid cap | −25.59% |
| WAY | Waystar Holding Corp. | $4.64B | Mid cap | −32.56% |
| HIK.L | Hikma Pharmaceuticals PLC | $4.63B | Mid cap | −11.37% |
| ICUI | ICU Medical, Inc. | $4.56B | Mid cap | +44.85% |
| OBCK.DE | Ottobock SE & Co. KGaA I | $4.51B | Mid cap | −0.82% |
| DOCS | Doximity, Inc. | $4.51B | Mid cap | −62.74% |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +486.04% |
| ELVN | Enliven Therapeutics, Inc. | $4.48B | Mid cap | +205.89% |
| 128940.KS | Hanmi Pharm. Co., Ltd. | $4.47B | Mid cap | +80.49% |
| CELC | Celcuity Inc. | $4.44B | Mid cap | +87.35% |
| CON | Concentra Group Holdings Parent, Inc. | $4.44B | Mid cap | +49.74% |
| NVST | Envista Holdings Corporation | $4.39B | Mid cap | +30.07% |
| LIVN | LivaNova PLC | $4.37B | Mid cap | +40.92% |
| HTFL | Heartflow, Inc. | $4.34B | Mid cap | +67.19% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.26% |
| INDV | Indivior Pharmaceuticals, Inc. | $4.24B | Mid cap | +49.81% |
| ADPT | Adaptive Biotechnologies Corporation | $4.19B | Mid cap | +107.18% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.17B | Mid cap | +340.71% |
| ANN.AX | Ansell Limited | $4.17B | Mid cap | +22.31% |
| 4506.T | Sumitomo Pharma Co., Ltd. | $4.16B | Mid cap | −2.73% |
| LEGN | Legend Biotech Corporation | $4.14B | Mid cap | −38.44% |
| TNGX | Tango Therapeutics, Inc. | $4.13B | Mid cap | +264.73% |
| MANE | Veradermics, Incorporated | $4.11B | Mid cap | +171.13% |
| IDYA | IDEAYA Biosciences, Inc. | $4.10B | Mid cap | +71.91% |
| IRTC | iRhythm Holdings, Inc. | $4.06B | Mid cap | −25.71% |
| ABCL | AbCellera Biologics Inc. | $4.05B | Mid cap | +195.51% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.04B | Mid cap | −0.90% |
| RCUS | Arcus Biosciences, Inc. | $4.02B | Mid cap | +211.03% |
| VKTX | Viking Therapeutics, Inc. | $3.99B | Mid cap | +32.19% |
| DNLI | Denali Therapeutics Inc. | $3.98B | Mid cap | +60.12% |
| TLX | Telix Pharmaceuticals Limited | $3.96B | Mid cap | −4.26% |
| MCOV-B.ST | Medicover AB (publ) | $3.91B | Mid cap | −10.12% |
| TLX.AX | Telix Pharmaceuticals Limited | $3.91B | Mid cap | −12.72% |
| BBZA.DE | BB Biotech AG | $3.90B | Mid cap | +7.22% |
| 000105.KS | Yuhan Corporation | $3.88B | Mid cap | −31.05% |
| CAMX.ST | Camurus AB (publ) | $3.87B | Mid cap | −14.52% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +52.72% |
| FIE.DE | Fielmann Group AG | $3.85B | Mid cap | −30.39% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +233.60% |
| 4536.T | Santen Pharmaceutical Co., Ltd. | $3.80B | Mid cap | +22.85% |
| 7459.T | MediPal Holdings Corporation | $3.77B | Mid cap | +14.74% |
| GRAL | GRAIL, Inc. | $3.69B | Mid cap | +150.69% |
| OGN | Organon & Co. | $3.61B | Mid cap | +52.78% |
| A2LC34.SA | Alcon Inc. | $3.57B | Mid cap | −12.91% |
| GPCR | Structure Therapeutics Inc. | $3.56B | Mid cap | +168.82% |
| QURE | uniQure N.V. | $3.54B | Mid cap | +228.30% |
| OPCH | Option Care Health, Inc. | $3.54B | Mid cap | −15.75% |
| VCYT | Veracyte, Inc. Common Stock | $3.54B | Mid cap | +49.04% |
| NHC | National HealthCare Corporation | $3.52B | Mid cap | +103.48% |
| PLSE | Pulse Biosciences, Inc. | $3.50B | Mid cap | +197.94% |
| ZEAL.CO | Zealand Pharma A/S | $3.48B | Mid cap | −27.05% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +196.22% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.33B | Mid cap | +275.00% |
| MBX | MBX Biosciences, Inc. | $3.30B | Mid cap | +394.02% |
| 3349.T | COSMOS Pharmaceutical Corporation | $3.27B | Mid cap | −27.10% |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.27B | Mid cap | +10.69% |
| AFX.DE | Carl Zeiss Meditec AG | $3.26B | Mid cap | −23.23% |
| WRBY | Warby Parker Inc. | $3.24B | Mid cap | −0.61% |
| BIOA-B.ST | BioArctic AB (publ) | $3.24B | Mid cap | +20.03% |
| CLDX | Celldex Therapeutics, Inc. | $3.24B | Mid cap | +87.96% |
| TMDX | TransMedics Group, Inc. | $3.23B | Mid cap | −18.59% |
| VIRP.PA | Virbac SA | $3.22B | Mid cap | −2.81% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | +88.75% |
| AMBU-B.CO | Ambu A/S | $3.20B | Mid cap | −19.61% |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.20B | Mid cap | +26.21% |
| 7649.T | Sugi Holdings Co.,Ltd. | $3.19B | Mid cap | −28.33% |
| IRON | Disc Medicine, Inc. | $3.16B | Mid cap | +38.71% |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +58.44% |
| ASKER.ST | Asker Healthcare Group AB (publ) | $3.03B | Mid cap | −22.60% |
| HYPE3.SA | Hypera S.A. | $2.98B | Mid cap | −4.08% |
| ALMS | Alumis Inc. | $2.98B | Mid cap | +388.98% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +82.91% |
| ZLAB | Zai Lab Limited | $2.94B | Mid cap | −23.10% |
| BKD | Brookdale Senior Living Inc. | $2.91B | Mid cap | +59.90% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.89B | Mid cap | +637.70% |
| ALHC | Alignment Healthcare, Inc. | $2.82B | Mid cap | −12.77% |
| ACHC | Acadia Healthcare Company, Inc. | $2.78B | Mid cap | +34.73% |
| 9989.T | Sundrug Co.,Ltd. | $2.76B | Mid cap | −17.00% |
| RGC | Regencell Bioscience Holdings Limited | $2.74B | Mid cap | −54.89% |
| VRDN | Viridian Therapeutics, Inc. | $2.74B | Mid cap | +30.21% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +56.96% |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | Mid cap | +178.70% |
| EBO.AX | EBOS Group Limited | $2.72B | Mid cap | −35.38% |
| PRVA | Privia Health Group, Inc. | $2.71B | Mid cap | −0.93% |
| AXGN | AxoGen, Inc. Common Stock | $2.68B | Mid cap | +237.59% |
| CDNA | CareDx, Inc. | $2.63B | Mid cap | +298.43% |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.62B | Mid cap | +2.09% |
| PHVS | Pharvaris N.V. | $2.62B | Mid cap | +57.76% |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −9.60% |
| WGS | GeneDx Holdings Corp. | $2.61B | Mid cap | −28.28% |
| B72.DE | AtaiBeckley Inc. | $2.60B | Mid cap | +57.16% |
| CURA.TO | Curaleaf Holdings, Inc. | $2.60B | Mid cap | +225.42% |
| EMEIS.PA | EMEIS | $2.60B | Mid cap | +10.18% |
| PGEN | Precigen, Inc. | $2.60B | Mid cap | +82.91% |
| BV3.DE | BAVARIAN NORDIC N | $2.59B | Mid cap | +14.47% |
| BAVA.CO | Bavarian Nordic A/S | $2.58B | Mid cap | −10.13% |
| 2784.T | Alfresa Holdings Corporation | $2.57B | Mid cap | +7.97% |
| TRVI | Trevi Therapeutics, Inc. | $2.56B | Mid cap | +146.57% |
| VERA | Vera Therapeutics, Inc. | $2.54B | Mid cap | +65.32% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +107.86% |
| BHC.TO | Bausch Health Companies Inc. | $2.52B | Mid cap | −8.00% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +176.20% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +17.16% |
| BHC | Bausch Health Companies Inc. | $2.50B | Mid cap | −7.81% |
| 3549.T | Kusuri No Aoki Holdings Co., Ltd. | $2.50B | Mid cap | +6.99% |
| NUVB | Nuvation Bio Inc. | $2.49B | Mid cap | +146.53% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +316.68% |
| ATRC | AtriCure, Inc. | $2.48B | Mid cap | +28.65% |
| PBH | Prestige Consumer Healthcare Inc. | $2.46B | Mid cap | −21.64% |
| RAPP | Rapport Therapeutics, Inc. | $2.46B | Mid cap | +249.76% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.44B | Mid cap | +63.50% |
| ONT.L | Oxford Nanopore Technologies plc | $2.44B | Mid cap | −14.60% |
| DMP.DE | Dermapharm Holding SE | $2.43B | Mid cap | +14.86% |
| BFLY | Butterfly Network, Inc. | $2.41B | Mid cap | +483.23% |
| OCUL | Ocular Therapeutix, Inc. | $2.39B | Mid cap | −8.34% |
| GRDN | Guardian Pharmacy Services, Inc. | $2.36B | Mid cap | +42.20% |
| UFPT | UFP Technologies, Inc. | $2.36B | Mid cap | +37.69% |
| MLYS | Mineralys Therapeutics, Inc. | $2.32B | Mid cap | +78.70% |
| 009420.KS | Hanall Biopharma Co., Ltd. | $2.32B | Mid cap | +108.57% |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.32B | Mid cap | +46.03% |
| ALMR | Alamar Biosciences, Inc. | $2.29B | Mid cap | +50.09% |
| GENB | Generate Biomedicines, Inc. | $2.27B | Mid cap | +61.11% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.27B | Mid cap | +4.09% |
| URGN | UroGen Pharma Ltd. | $2.27B | Mid cap | +150.59% |
| EKTA-B.ST | Elekta AB (publ) | $2.27B | Mid cap | +19.21% |
| ADUS | Addus HomeCare Corporation | $2.26B | Mid cap | +3.81% |
| 008930.KS | Hanmi Science Co., Ltd. | $2.26B | Mid cap | +10.13% |
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | −3.82% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +9.42% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.23B | Mid cap | +38.03% |
| VCEL | Vericel Corporation | $2.21B | Mid cap | +20.76% |
| ZBIO | Zenas BioPharma, Inc. | $2.20B | Mid cap | +103.93% |
| CLOV | Clover Health Investments, Corp. | $2.19B | Mid cap | +56.14% |
| MD | Pediatrix Medical Group, Inc. | $2.19B | Mid cap | +58.21% |
| XRAY | DENTSPLY SIRONA Inc. | $2.19B | Mid cap | −21.70% |
| NEO | NeoGenomics, Inc. | $2.19B | Mid cap | +160.31% |
| XNCR | Xencor, Inc. Common Stock | $2.18B | Mid cap | +265.79% |
| EXE.TO | Extendicare Inc. | $2.18B | Mid cap | +147.28% |
| BHVN | Biohaven Ltd. | $2.17B | Mid cap | −3.75% |
| 9987.T | Suzuken Co., Ltd. | $2.17B | Mid cap | −11.16% |
| STOK | Stoke Therapeutics, Inc. | $2.16B | Mid cap | +77.32% |
| CLOV34.SA | Clover Health Investments, Corp. | $2.15B | Mid cap | +44.32% |
| ESTA | Establishment Labs Holdings Inc. | $2.15B | Mid cap | +77.45% |
| GN.CO | GN Store Nord A/S | $2.15B | Mid cap | −19.72% |
| KLRA | Kailera Therapeutics, Inc. | $2.14B | Mid cap | −31.73% |
| ADMA | ADMA Biologics, Inc. | $2.14B | Mid cap | −42.86% |
| PVLA | Palvella Therapeutics, Inc. | $2.14B | Mid cap | +195.71% |
| 302440.KS | SK bioscience Co.,Ltd. | $2.13B | Mid cap | −22.23% |
| HCM | HUTCHMED (China) Limited | $2.13B | Mid cap | −23.04% |
| HCM.L | HUTCHMED (China) Limited | $2.12B | Mid cap | −21.24% |
| NANO.PA | Nanobiotix S.A. | $2.12B | Mid cap | +341.09% |
| NBTX | Nanobiotix S.A. | $2.11B | Mid cap | +321.42% |
| ALIF-B.ST | AddLife AB (publ) | $2.09B | Mid cap | −7.56% |
| GNS.L | Genus plc | $2.08B | Mid cap | −13.32% |
| NEU.AX | Neuren Pharmaceuticals Limited | $2.08B | Mid cap | +18.47% |
| PIII | P3 Health Partners Inc. | $2.06B | Mid cap | +35.72% |
| CMPS | COMPASS Pathways plc | $2.06B | Mid cap | +224.89% |
| NVCR | NovoCure Limited | $2.05B | Mid cap | +50.60% |
| SEM | Select Medical Holdings Corp | $2.05B | Mid cap | +26.87% |
| 6960.T | Fukuda Denshi Co., Ltd. | $2.02B | Mid cap | +78.59% |
| TSHA | Taysha Gene Therapies, Inc. | $2.02B | Mid cap | +112.33% |
| PRGO | Perrigo Company plc | $2.01B | Mid cap | −36.97% |
| EMBLA.CO | Embla Medical hf | $2.00B | Mid cap | −5.76% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.